Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR3 | P25089 | 2/20 | 0.31 |
| ▸ | FPR2 | P25090 | 2/20 | 0.31 |
| ▸ | ESRRB | O95718 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESRRA | P11474 | 1/20 | 0.31 |
| ▸ | ESRRG | P62508 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.30 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13746501 | 1.00 | FPR3 (0.31) | FPR3FPR2ESRRBESR1ESRRA | |
| SCHEMBL10182263 | 0.80 | NPC1 (0.46) | FPR3FPR2 | |
| SCHEMBL19488759 | 0.79 | NPC1 (0.43) | FPR3FPR2 | |
| SCHEMBL10182417 | 0.78 | KMT2A (0.41) | — | |
| SCHEMBL12752017 | 0.78 | KMT2A (0.41) | — | |
| SCHEMBL15586735 | 0.78 | KMT2A (0.41) | — | |
| SCHEMBL15773712 | 0.78 | KMT2A (0.41) | — | |
| SCHEMBL19488754 | 0.73 | FPR2 (0.38) | FPR3FPR2 | |
| SCHEMBL10202447 | 0.73 | FPR2 (0.38) | FPR3FPR2 | |
| SCHEMBL1294187 | 0.72 | ALDH1A1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8147818-B2 | inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8147818-B2 | inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | FPR3 2547/4885FPR2 3812/4885ESRRB 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.